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eye disease: A multicenter, double-masked, randomized 30-day study
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Purpose: In a randomized, controlled clinical trial, two lubricant artiﬁcial tear formulations with enhanced
viscosity were compared: an investigational product at the time, containing carboxymethylcellulose 1.0% and
glycerin 0.9% (CMC-GLY) with osmoprotectants, and a standard formula containing carboxymethylcellulose
1.0% alone (CMC).
Methods: This double-masked study recruited patients with moderate to severe dry eye at 10 US centers. After a
7-day run-in with CMC 0.5% (Refresh Tears) patients were randomized to use either CMC-GLY or CMC as
needed, but at least 2 times daily for 30 days. Patients were stratiﬁed by Ocular Surface Disease Index© (OSDI)
score into moderate (23–32) and severe (> 32–65) subgroups. Assessments included OSDI (primary eﬃcacy
variable), corneal and conjunctival staining, tear break-up time (TBUT), symptom surveys, and safety variables.
Study visits were days 1 (baseline/randomization), 7, and 30.
Results: A total of 188 patients (94 CMC-GLY, 94 CMC) were enrolled. The severe subgroup had 67 CMC-GLY
and 65 CMC patients. OSDI scores progressively improved and were similar at day 30 between treatment groups.
At day 7, only the CMC-GLY group demonstrated signiﬁcant improvements from baseline in OSDI score (all
patients p < 0.001, severe p < 0.001), corneal staining (p = 0.004), and TBUT (p < 0.001). Between-group
dose frequency for CMC-GLY was lower at day 7 (p = 0.031). Other eﬃcacy results were similar between groups.
The most commonly reported adverse event in both groups was blurred vision.
Conclusions: Overall, the CMC-GLY artiﬁcial tear formulation was as eﬀective as the CMC formulation. CMC-GLY
demonstrated improvements at an earlier stage (day 7). Both artiﬁcial tear formulations were safe and well
tolerated, with no treatment-related serious adverse events. These results support the use of the CMC-GLY artiﬁcial tear formulation as an eﬀective treatment to reduce the symptoms and signs of dry eye disease.

1. Introduction
Dry eye disease is a multifactorial disease of the ocular surface that
is estimated to cause symptoms in 5%–50% of the global population
[1,2]. Dry eye symptoms impact daily functions including reading,
driving, professional work, and social activities, signiﬁcantly

diminishing quality of life [3,4]. Artiﬁcial tears (lubricant eye drops or
gels) are often used as primary therapy for mild to moderate disease
and in combination with pharmacological agents or surgical procedures
in more severe disease [5,6]. With better understanding of the roles of
tears, tear ﬁlm osmolarity, and ocular surface inﬂammation in dry eye
disease [7–9], development of novel artiﬁcial lubricants has focused on
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(TBUT) tests ≤ 10 s in at least 1 eye, a distance visual acuity ≥ 20/32
Snellen equivalent in each eye (3-meter LogMAR chart with existing
correction), and intraocular pressure (IOP) ≤21 mm Hg in both eyes.
Subjects who discontinued use of pre-study artiﬁcial tears at screening,
received monotherapy for glaucoma or ocular hypertension, or had
used cyclosporine ophthalmic emulsion (Restasis®, Allergan plc, Dublin,
Ireland) for at least 3 months prior to screening with no anticipated
dosage adjustments were eligible for the study.
Key exclusion criteria included Schirmer test (with anesthesia)
≤2 mm/5 min in either eye at screening, corneal or conjunctival
staining score of 5 at screening or day 1 in any area of either eye, and
cumulative corneal staining score of > 18 in all 5 zones at screening or
day 1 in either eye. Subjects using systemic medications < 3 months
prior to screening that may have aﬀected a dry eye condition or vision,
with a history of prior ocular/ophthalmic surgery or trauma within 6
months prior to screening that could have aﬀected corneal sensitivity
and/or tear distribution, or currently using or having used topical
ocular medication within 2 weeks of screening were excluded. Subjects
being treated with both IOP-lowering medication and cyclosporine
ophthalmic emulsion were not considered for enrollment.

interaction with ocular surface cells, enhancing protection by preventing cell volume loss, cellular stress, and inﬂammatory reactions, as
well as eliminating damaging preservatives. For many patients with dry
eye, artiﬁcial tears with higher viscosity, or gel-type tears, are preferred
for their extended eﬃcacy due to enhanced ocular residence [10,11]. In
addition, these mid-viscosity gel-type tears are more suitable for
nighttime than conventional tears, yet are easier to apply for many
users than gel and ointment products in tubes. Overall, the more viscous
gel-type artiﬁcial tears are associated with greater improvements in
signs and symptoms of dry eye compared with standard low-viscosity
lubricating eye drops [12–14]. If viscosity is too high, it may reduce
tolerability due to blur, stickiness, and build-up of residue on the lids
and lashes; however, it is also essential that suﬃcient viscosity is retained under shear stress (during blinking) in order to maintain ocular
residence [15].
Carboxymethylcellulose sodium (CMC) is a well-established
polymer used in lubricating drops that has been shown to bind to the
corneal surface, increasing retention time and promoting corneal
wound healing [11,16–19]. CMC (1.0%) is the active ingredient in
Refresh Liquigel® Lubricant Eye Gel (Allergan plc, Dublin, Ireland), and
is approved for the temporary relief of burning, irritation, and discomfort due to dryness of the eye. Increasing the concentration of CMC
(e.g., from 0.5% to 1.0%) and/or the use of higher–molecular-weight
polymers enhances viscosity and ocular residence time [14]. A new
formulation (Refresh Optive® Gel Drops Lubricant Eye Gel, Allergan plc,
Dublin, Ireland) consists of a combination of CMC (1.0%) and glycerin
(0.9%) (CMC-GLY). The novel CMC-GLY formulation contains glycerin
as a second active ingredient, a small molecule that rapidly enters
ocular surface cells and assists in the maintenance of cell hydration and
normal osmotic balance [20]. CMC-GLY also contains L-carnitine and
erythritol as compatible solutes (osmoprotectants) providing osmotic
balance, and the preservative Purite®. These intracellular osmolytes
displace excessive salt [21,22], help maintain cell volume [21,22], and
protect against the pro-inﬂammatory hyperosmotic stress that is characteristic of dry eye [20,23].
The objective of this study was to evaluate the eﬃcacy, safety, and
patient acceptability of this new lubricant eye gel containing CMC 1.0%
and glycerin 0.9% in subjects with signs and symptoms of dry eye
disease, compared with the standard formula containing CMC 1.0%
alone (Refresh Liquigel).

2.3. Study treatment
The study consisted of a baseline visit (day 1) and 2 follow-up visits
at days 7 ( ± 3 days) and 30 ( ± 7 days; or early exit). At the screening
visit, all subjects who met inclusion/exclusion criteria received CMC
0.5% (Refresh Tears®; Allergan plc, Dublin, Ireland), and were asked to
instill 1–2 drops at least twice daily in each eye for 7 days (run-in
period) prior to the baseline visit. Following the run-in period, subjects
who still met study criteria were randomized 1:1 on day 1 to treatment
with CMC-GLY or CMC (1.0%) alone. Subjects were also stratiﬁed at
baseline according to their OSDI score into moderate (23–32) and severe (> 32–65) subgroups. An automated Interactive Voice Response
System or Interactive Web Response System Randomization was used to
manage randomization and treatment assignment based on a scheme
prepared by Allergan Biostatistics. Subjects were instructed to instill
1–2 drops of their assigned study product in each eye, as needed, but at
least twice daily for 30 days. Study products, as well as the run-in
product, were provided in identical 15-mL bottles to maintain subject
and investigator masking. Monitoring of treatment compliance was
achieved using the Study Product Usage Questionnaire at all follow up
visits; investigators also recorded the number of units dispensed and
unused units returned throughout the study.

2. Methods
2.1. Study design

2.4. Outcome measures
This double-masked, randomized, 2-arm, parallel-group study was
conducted at 10 clinical sites in the United States between November
2014 and March 2015 (ClinicalTrial.gov identiﬁer: NCT02280473). The
study was carried out in accordance with the International Conference
on Harmonisation guidelines for Good Clinical Practice. Investigators at
each site obtained study approval from their institutional review board
or an independent ethics committee, and all subjects provided written
informed consent prior to the start of any study procedures.

The change in OSDI score from baseline at day 30 was the primary
eﬃcacy variable. The OSDI is scored on a scale of 0 to 100 [24], with
higher scores representing more severe disease and a negative change
from baseline demonstrating improvement. The change from baseline
in OSDI score at day 7 was a secondary eﬃcacy variable. Additional
secondary eﬃcacy measures included TBUT measured 3 times in each
eye during the 2-min period following instillation of sodium ﬂuorescein
onto the superior bulbar conjunctiva. In each eye, corneal staining
evaluated in 5 zones with ﬂuorescein and interpalpebral conjunctival
staining evaluated in 6 zones with lissamine green were assessed using
the modiﬁed NEI Grid graded on a scale of 0 (no staining) to 5 (> 30
dots plus conﬂuence) [25]. Schirmer tests (with anesthesia) were performed in each eye after completing all other assessments, initiated
4 min after instillation of a drop of anesthesia and the amount of wetting of test strips measured 5 min later.
Other eﬃcacy assessments included 2 subject surveys: 1 concerning
current symptoms of burning/stinging, grittiness/foreign sensation,
dryness, diﬃcult/uncomfortable vision, and overall pain/discomfort,
and the other consisting of 10 questions about the short- and long-term
experience, primarily in comfort and vision, with the test products.

2.2. Inclusion and exclusion criteria
Healthy male or female subjects ≥18 years of age were enrolled if
they had moderate to severe symptoms according to an Ocular Surface
Disease Index© (OSDI) score ≥28 and ≤65 (based upon a 0–100 scale)
at screening and OSDI score ≥23 and ≤65 at the baseline visit.
Subjects were required to have used artiﬁcial tears at least twice daily
on average for at least 1 month prior to screening. Subjects had to have
grade ≥1 staining (modiﬁed National Eye Institute Grid score: range
0–5) in ≥1 area of the cornea (5 areas examined) or conjunctiva (6
areas examined) in at least 1 eye at screening and day 1. At screening,
subjects were also required to have 3 consecutive tear break-up time
444
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Grading ranged from 0 (none) to 100 (maximum) on a visual analog
scale. Subjects also reported their daily dosing frequency on average
over the past week and the timing of the last dose.
Safety assessments were performed in both eyes and included
monitoring adverse events (coded using the Medical Dictionary for
Regulatory Activities, version 18.0), biomicroscopy examinations performed in each eye (without pupil dilation), currently corrected distance visual acuity and best-corrected distance visual acuity measured
in each eye, and IOP (with anesthesia and ﬂuorescein) assessed in each
eye at approximately the same time at each visit using the Goldmann
applanation tonometer.

3. Statistical analysis
The intent-to-treat (ITT) population consisting of all randomized
subjects was used for eﬃcacy analysis based on the randomized treatment. The per protocol population, consisting of randomized subjects
with no signiﬁcant protocol violations prior to database lock, was used
for sensitivity eﬃcacy analysis. The safety population, consisting of all
subjects receiving at least one treatment dose, was used for safety
analysis based on the actual treatment received.
The primary eﬃcacy analysis of the change from baseline in OSDI
score at day 30 was performed using an analysis of variance (ANOVA)
model, with treatment and stratiﬁcation factors based on baseline OSDI
score (moderate or severe) as ﬁxed eﬀects. Analysis was performed on
the ITT population using the last observation carried forward method
following a strategy of combined noninferiority and superiority tests
[26]. Noninferiority was tested using the conﬁdence interval (CI) procedure, and if the upper limit of the 2-sided 95% CI based on treatment
diﬀerence (CMC-GLY minus CMC) was less than 7.3 units [27], then the
CMC-GLY formulation was considered noninferior to CMC. The change
from baseline in the OSDI score at day 7 was analyzed using the same
model described above for the primary eﬃcacy variable. Descriptive
statistics of change from baseline in the OSDI score for each visit were
tabulated and within-group changes from baseline were analyzed using
the paired t test at each visit. Subgroup analysis of baseline and change
from baseline in OSDI scores, based on baseline OSDI score stratum
(moderate vs severe), was performed in the ITT population using a 1way ANOVA model with treatment as the ﬁxed eﬀect.
For other eﬃcacy measures including TBUT, corneal and conjunctival staining, and Schirmer test, the worse eye at baseline was used
for analysis. Continuous variables were summarized using descriptive
statistics, and analyzed using ANOVA models or Wilcoxon Rank Sum
test for between-group diﬀerences and paired t tests for within-group
diﬀerences. Categorical variables were summarized by frequency and
percentage, and were analyzed using Pearson’s chi-square test or
Fisher’s exact-test. For safety, the number and percentage of all adverse
events reported were tabulated for each treatment group.
Biomicroscopy ﬁndings, currently corrected distance visual acuity, bestcorrected distance visual acuity, and IOP measures were summarized
with descriptive statistics and the frequency distributions analyzed
using Pearson’s chi-square test or Fisher’s exact-test, where appropriate.
To obtain 85% power for a 1-sided noninferiority test for a betweengroup diﬀerence of 7.3 units in mean change from baseline in total
OSDI score at day 30, 85 subjects per treatment group were required
based on a 1-sided type I error rate of 0.025 and the assumptions of no
inherent treatment diﬀerence and a common standard deviation (SD) of
15.7. With a 1:1 treatment allocation and combined dropout and protocol deviation rate of 5%, a total of 180 subjects were required to be
enrolled to have 170 subjects complete the study through day 30.
Sample size and power calculations were performed using procedure
MTE0-1 of the nQuery Advisor software, version 6.01 (Statistical
Solutions, Boston, MA, US).

Fig. 1. Subject ﬂow diagram. CMC = carboxymethylcellulose
GLY = glycerin 0.9%, ITT = intent-to-treat.

1.0%,

4. Results
4.1. Subject disposition and baseline characteristics
A total of 188 subjects were enrolled and received CMC 0.5% alone
during a 7-day masked run-in period, after which they were randomized to receive treatment with CMC-GLY (94 subjects; 67 with severe
disease) or CMC 1.0% alone (94 subjects; 65 with severe disease). Of
the randomized subjects, 184 (97.9%) went on to complete the study.
Four (2.1%) subjects discontinued during the course of the study: due to
adverse events (n = 2 [1.1%]), lack of eﬃcacy (n = 1 [0.5%]) and loss
to follow-up (n = 1 [0.5%]) (Fig. 1). There were no signiﬁcant diﬀerences in subject characteristics and baseline clinical assessments between the treatment groups (Table 1). Mean (SD) age of subjects was
51.2 (15.4) years, and most (n = 139 [73.9%]) were over 40 years of
Table 1
Demographics and baseline characteristics.
Characteristic

CMC-GLY
(n = 94)

CMC (n = 94)

P valuea

Mean (SD) age, years
> 40, n (%)
Sex, n (%)
Female
Male
Race, n (%)
Caucasian
Non-Caucasian
Mean OSDI score (SD)
Moderate disease (OSDI 23–32)
Severe disease (OSDI > 32)
Mean TBUT (SD), sec
Mean Schirmer’s test (SD), mm/
5 min
Mean staining score (SD)
Combined corneal/conjunctival
Corneal
Conjunctival

51.7 (14.8)
72 (76.6)

50.7 (15.9)
67 (71.3)

0.633

78 (83.0)
16 (17.0)

75 (79.8)
19 (20.2)

83 (88.3)
11 (11.7)
42.4 (11.7)
28.6 (2.5)
48.0 (9.0)
5.4 (1.7)
10.0 (7.2)

84 (89.4)
10 (10.6)
40.4 (11.2)
28.6 (2.6)
45.7 (9.4)
5.4 (2.1)
11.3 (8.5)

0.968b
0.244b

10.9 (7.2)
4.9 (3.7)
6.2 (4.8)

11.8 (7.2)
5.0 (3.6)
7.1 (4.8)

0.261c
0.683c
0.196c

0.574

0.817

0.230b

CMC = carboxymethylcellulose 1.0%, GLY = glycerin 0.9%, OSDI = Ocular
Surface Disease Index©, SD = standard deviation, TBUT = tear break-up time.
a
2-sample t test for continuous variables; Pearson's chi-square test for categorical variables.
b
Analysis of variance model with treatment as the ﬁxed eﬀect.
c
Wilcoxon Rank Sum test.
445
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4.2. Eﬃcacy outcomes
Signiﬁcant improvements in OSDI score from baseline were observed with CMC-GLY at both days 7 and 30 (p < 0.001), and with
CMC at day 30 (p < 0.001) (Fig. 2 and Table 2). At day 30, the mean
(SD) change in OSDI score from baseline was −10.3 (15.9) for CMCGLY and −7.5 (16.6) for CMC. In the primary eﬃcacy analysis, the
criterion for noninferiority of CMC-GLY compared with CMC was met:
the least squares mean diﬀerence between the treatment groups was
−2.7 with a 95% CI of (−7.4, 1.9); the upper limit of the 95% CI was
below the prespeciﬁed clinical margin of 7.3. Superiority testing indicated that between-group diﬀerences in the mean change from
baseline in OSDI score were not signiﬁcantly diﬀerent at any follow-up
visit.
In the subgroup analysis, signiﬁcant improvements in OSDI score
from baseline were observed following treatment with CMC-GLY in the
moderate disease (OSDI score: 23–32) subgroup at day 30 (p = 0.001)
and in the severe disease (OSDI score: > 32) subgroup at days 7 and 30
(p < 0.001). Treatment with CMC also resulted in signiﬁcant improvements in OSDI score from baseline in the moderate (p < 0.05)
and severe (p < 0.001) subgroups at day 30 (Fig. 2).There were no
signiﬁcant diﬀerences between CMC-GLY and CMC in the mean change
from baseline in OSDI scores at days 7 and 30, among subjects who had
moderate or severe OSDI scores at baseline.
Signiﬁcant improvements from baseline in TBUT were observed
following treatment with CMC-GLY at days 7 (p < 0.001) and 30
(p = 0.002) and with CMC at day 30 (p < 0.001) (Fig. 3 and Table 2).
Combined corneal/conjunctival staining signiﬁcantly improved from
baseline in both the CMC-GLY and CMC groups at days 7 and 30
(p ≤ 0.02) (Fig. 4). Corneal staining was signiﬁcantly improved from
baseline in only the CMC-GLY group at days 7 and 30 (p ≤ 0.017; Fig. 4
and Table 2), while conjunctival staining was signiﬁcantly improved in
both the CMC-GLY and CMC groups at days 7 and 30 (p ≤ 0.019)
(Fig. 4). No statistically signiﬁcant diﬀerences were observed between
treatment groups in the mean change from baseline in TBUT, combined
corneal/conjunctival staining, corneal staining, and conjunctival
staining. There were no statistically signiﬁcant diﬀerences within or
between the CMC-GLY and CMC groups for the mean change from
baseline in Schirmer test score at each follow-up visit. At day 30, the
mean (SD) change from baseline in Schirmer test score was 0.8 (5.5)
mm/5 min for CMC-GLY and 0.5 (6.6) mm/5 min for CMC.
Results of the current symptom and eye drop experience surveys
were generally comparable between the treatment groups. Both treatment groups demonstrated signiﬁcant improvements in eye dryness
score from baseline with a mean (SD) change of −8.1 (24.6) for CMCGLY (p = 0.002) and −16.2 (28.7) for CMC (p < 0.001). A signiﬁcant
between-group diﬀerence was observed in the change from baseline in
dryness score in favor of CMC at day 30 (p = 0.037). No signiﬁcant
diﬀerences between the CMC-GLY and CMC groups were observed for
mean change in burning/stinging, grittiness/foreign body sensation,
diﬃcult/uncomfortable vision, and overall ocular pain/discomfort
scores. At day 30, there were no signiﬁcant between-group diﬀerences
for the following 8 (of the 10) eye drop experience questions: ﬁrst application experience of the eye drop in terms of “no burning or
stinging”, “no blurring or interference with vision”, “feels substantial
and optimally thick”; within 5 min after application, “relief of dry eye
discomfort”; and within the past few days, “did not cause eyes/eyelashes to become matted/crusty”, “vision is clear and comfortable”,
“long lasting relief of dry eye discomfort”, and “overall liked these eye
drops”. For questions regarding eye comfort at ﬁrst application of study
product (69.1 [30.0] vs 59.3 [32.8]; p = 0.041) and vision interference
within 10 min of application of study product (70.7 [31.8] vs 57.3
[36.5]; p = 0.009), CMC elicited a more favorable mean (SD) response
compared with CMC-GLY. Usage of CMC-GLY was lower than that of
CMC at day 7 (mean [SD]: 2.7 [1.0] vs 3.2 [1.7] drops/day, p = 0.031)
and similar at day 30 (mean [SD]: 2.7 [0.9] vs 3.0 [1.2] drops/day,

Fig. 2. Change in Ocular Surface Disease Index© (OSDI) score from baseline in
(A) all subjects (n = 188), (B) subjects (n = 56) with moderate dry eye (OSDI
score 23 to 32) and (C) subjects (n = 132) with severe dry eye (OSDI score >
32) at baseline. Data points represent mean ± standard error mean in the
intent-to-treat population; *p ≤ 0.001; †p = 0.046 by paired t test.
CMC = carboxymethylcellulose 1.0%, GLY = glycerin 0.9%. P values represent
within-group change from baseline.

age. The majority of subjects were female (n = 153 [81.4%]) and
Caucasian (n = 167 [88.8%]). Based on the reduced TBUT (5.4 s) and
normal Schirmer scores (≥10 mm/5 min) at baseline, the majority of
subjects had evaporative dry eye.
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Table 2
Change from baseline and between group comparison at day 7 and day 30 in OSDI score, corneal staining, TBUT, and dose frequency.
Eﬃcacy measure

OSDI
TBUT
Corneal staining
Dose frequency

Treatment

CMC-GLY
CMC
CMC-GLY
CMC
CMC-GLY
CMC
CMC-GLY
CMC

Day 7

Day 30

Change from baseline comparison

Between group comparison

Change from baseline comparison

Between group comparison

p < 0.001
NS
p < 0.001
NS
p = 0.004
NS
p = 0.025
(2.7 drops/daya)
NS
(3.2 drops/daya)

NS

p < 0.001
p < 0.001
p = 0.002
p < 0.001
p = 0.017
NS
p = 0.008
(2.7 drops/daya)
p = 0.476
(3.0 drops/daya)

NS

NS
NS
p = 0.031

NS
NS
NS

CMC = carboxymethylcellulose 1.0%, GLY = glycerin 0.9%, NS = non-signiﬁcant.
a
Mean patient reported drop use.

biomicroscopy ﬁndings were hyperemia (4 [4.3%] with CMC-GLY and
5 [5.3%] with CMC) and edema (3 [3.2%] with CMC-GLY and 2 [2.1%]
with CMC). There were no signiﬁcant diﬀerences between the 2 treatment groups in the frequency distribution of change from baseline in
currently corrected distance visual acuity or best-corrected distance
visual acuity at days 7 or 30. Intraocular pressure in the eye with the
worse change from baseline at each visit was similar between treatment
groups; mean change (IOP increase) from baseline at days 7 and 30 was
≤ 0.6 mm Hg with both CMC-GLY and CMC.
5. Discussion
Artiﬁcial tears (lubricant drops and gels) are often employed as the
primary treatment option for dry eye, to supplement the deﬁcient tear
ﬁlm critical for ocular comfort and adequate vision. There are a number
of gel-based artiﬁcial tear formulations, each with diﬀerent physicochemical properties (e.g., viscoelasticity) due to the presence of various
polymers or osmoprotectants. The concentration, types of polymers,
osmotic balance, use of osmoprotectants, type of preservative, buﬀer,
and combination of these ingredients may distinguish one formulation
from another with respect to improvements in signs and symptoms, as
well as tolerability.
In this study, a novel CMC-GLY lubricant eye gel formulation was
found to be noninferior to the standard formula containing CMC alone
in terms of dry eye symptom relief. Both formulations were associated
with signiﬁcant improvements in signs and symptoms of dry eye after
30 days. Symptoms were signiﬁcantly improved with CMC-GLY and
CMC at day 30 in the overall population and in subgroups stratiﬁed by
dry eye severity, and with CMC-GLY at day 7 in the overall population
and the severe dry eye subgroup. Based on reported minimal clinically
important diﬀerence thresholds for the OSDI in patients with mildmoderate dry eye (4.5–7.3) and severe dry eye (7.3–13.4) [27], and the
magnitude of OSDI change in the overall population and dry eye subgroups in this study, both formulations appear to provide clinically
relevant improvements in dry eye symptoms.
No between-group diﬀerences were observed in any other outcome
measures. TBUT signiﬁcantly improved from baseline in both CMC-GLY
and CMC groups at day 30, and in the CMC-GLY group at day 7. In each
case, the change in TBUT was below the 5 s threshold considered a
clinically important diﬀerence in the recent dry eye guidelines [28].
CMC-GLY and CMC demonstrated signiﬁcant improvements from
baseline in combined (corneal and conjunctival) and conjunctival
staining at day 30 and at day 7, and the CMC-GLY group had signiﬁcant
improvement in corneal staining at both day 30 and day 7. Ocular
symptoms also improved from baseline in both groups, but there were
no signiﬁcant changes in Schirmer test score. A signiﬁcant diﬀerence
was observed in 2 of 10 questions regarding experience with study
product at day 30 and reported product use at day 7, in favor of CMC.

Fig. 3. Change from baseline in tear break-up time (TBUT). Data points represent mean ± standard error mean in the intent-to-treat population;
*p < 0.001; †p = 0.002 by paired t test. CMC = carboxymethylcellulose 1.0%,
GLY = glycerin 0.9%. CMC-GLY (n = 94, 94, 93) and CMC (n = 94, 93, 91) at
baseline, day 7 and 30, respectively. P values represent within-group change
from baseline.

p = 0.073). Furthermore, usage of CMC-GLY at both days 7 (2.7 [0.96]
drops/day) and 30 (2.7 [0.90] drops/day) was statistically signiﬁcantly
less (p = 0.025 at day 7 and p = 0.008 at day 30) versus baseline run-in
product usage (3.0 [1.24] drops/day) (Table 2).

4.3. Safety
Adverse events of any causality were reported for 14 (14.9%) subjects in both CMC-GLY and CMC groups (Table 3). Treatment-related
adverse events occurred in 8 (8.5%) subjects in the CMC-GLY and 7
(7.4%) subjects in the CMC group; blurred vision was the most common
treatment-related adverse event (7 [7.4%] subjects receiving CMC-GLY;
5 [5.3%] subjects receiving CMC). Two subjects discontinued the study
due to treatment-emergent adverse events: 1 subject in the CMC-GLY
group experienced blurred vision and conjunctival hyperemia and 1
subject in the CMC group had corneal abrasion (not considered treatment-related by the investigator). One subject in the CMC group experienced a serious adverse event of hyphema that was not considered
treatment-related by the investigator and resolved on the same day it
occurred. No deaths were reported in the study.
Clinically signiﬁcant biomicroscopy ﬁndings (deﬁned as more than
1 severity grade increase [worsening] from baseline) in either eye at 1
or more visits were reported in 9 (9.6%) subjects in the CMC-GLY group
and 13 (13.8%) subjects in the CMC group. The most common
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Table 3
Summary of adverse events reported in the CMC-GLY and CMC treatment
groups.
Adverse event type, n (%)

CMC-GLY
(n = 94)

CMC
(n = 94)

Treatment-emergent adverse eventsa
Blurred vision
Conjunctival hemorrhage
Vital dye staining present in cornea
Treatment-related treatment-emergent adverse events
Blurred vision
Instillation site pruritus
Meibomianitis
Ocular discomfort
Eye irritation
Eye pruritus
Instillation site pain
Lacrimation increased
Medication residue present
Visual acuity reduced
Treatment-emergent serious adverse events

14 (14.9)
7 (7.4)
1 (1.1)
1 (1.1)
8 (8.5)
7 (7.4)
1 (1.1)
1 (1.1)
1 (1.1)
0
0
0
0
0
0
0 (0.0)

14 (14.9)
5 (5.3)
1 (1.1)
1 (1.1)
7 (7.4)
5 (5.3)
0
0
0
1 (1.1)
1 (1.1)
1 (1.1)
1 (1.1)
1 (1.1)
1 (1.1)
1 (1.1)

CMC, carboxymethylcellulose 1.0%; GLY, glycerin 0.9%.
a
Treatment-emergent adverse events occurring in at least 2 or more subjects
overall.

[31].
CMC-GLY was designed for patients with dry eye who require a
more viscous lubricating tear for management of their disease.
However, the potential for blurred vision with high-viscosity artiﬁcial
tears can limit the application of more viscous tears to overnight
treatment [32]. Despite the potential for higher rates of blurred vision
with products exhibiting higher viscosity, in this study the number of
subjects who experienced blurred vision was similar between the CMCGLY (n = 7) and the CMC-only formulation (n = 5). Furthermore, there
were no diﬀerences between CMC-GLY and CMC-only formulations for
the eye drop experience questions related to “no blurring or visual interference” upon immediate application, and “vision is clear and comfortable” within a few days of application. Diﬀerences in eye comfort at
ﬁrst application and visual interference within 10 min of application
reported by subjects, in favor of CMC, are probably related to the increased viscosity in the CMC-GLY formulation. Nevertheless, this
transient discomfort is oﬀset by the earlier improvement in signs and
symptoms of dry eye which can be attributed to the presence of glycerin
and osmoprotective solutes. It is also worth considering potential discrepancies in objective and subjective assessments of blurred vison in
this study.
The inclusion of humectant polymers, such as CMC, in gel-type artiﬁcial tears helps lubricate and hydrate the ocular surface, while increasing viscosity and ocular residency time. This allows for the application of gel-type tears during the day and also at night. Viscosity can
be enhanced by reducing the salt content (ie. substitution with osmoprotective solutes), which in turn increases the anionic charge strength
of CMC, and by the addition of glycerin, which has a synergistic eﬀect
[33]. Furthermore, the inclusion of osmoprotectants such as glycerin
protects against hyperosmolarity and may help reduce ocular surface
damage and visual disturbance [34,35].
. The signiﬁcant improvements observed with CMC-GLY in terms of
OSDI, TBUT and corneal staining at day 7 were achieved with signiﬁcantly fewer daily doses of CMC-GLY versus CMC alone, which
suggests that doubling the CMC content (from 0.5% in the run-in period
to 1.0% in both treatment arms) is less important than the addition of
glycerin and osmoprotectants.
In this controlled clinical trial, similar overall performance was
observed for both formulations. These results emphasize the variability
of response by individual dry eye patients; however, the availability of
multiple treatment options should beneﬁt practitioners and facilitate an
individually-tailored approach to the management of dry eye. The

Fig. 4. Change from baseline in (A) combined corneal/conjunctival staining,
(B) corneal staining, and (C) conjunctival staining score. Data points represent
mean ± standard error mean in the intent-to-treat population; *p < 0.01;
†
p < 0.05 by Wilcoxon signed-rank test. CMC = carboxymethylcellulose 1.0%,
GLY = glycerin 0.9%. CMC-GLY (n = 94, 94, 93) and CMC (n = 94, 93, 91) at
baseline, day 7 and 30, respectively. P values represent within-group change
from baseline.

Both the CMC-GLY and CMC-only formulations were well tolerated
during the study, with similar favorable safety proﬁles.
The magnitude of the improvement in symptoms, TBUT and
Schirmer scores reported in this study are similar to those reported at 4
weeks in dry eye studies that previously investigated CMC-GLY [29,30],
and carbomer-based lipid gels and hydroxypropyl guar gel formulations
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earlier beneﬁt observed with CMC-GLY and need for less frequent
dosing is likely desirable for patients, and may outweigh any potential
for discomfort upon initial application for some patients. Further studies could explore patient preference while rheological studies could
evaluate viscosity under shear stress in gel-based formulations to determine which components provide optimal performance in terms of
symptom improvement and tolerability. A number of osmoprotectants,
including L-carnitine and erythritol, have already shown a potential
anti-inﬂammatory eﬀect in corneal epithelial cells under osmotic stress
[36]. Additional studies that include measures of markers of cellular
stress could help elucidate eﬀects of the additional components in the
CMC-GLY formulation. In addition, studies evaluating the eﬀectiveness
of the novel lubricant eye gel in speciﬁc subpopulations of patients with
dry eye may assist eye care practitioners in treatment decisions.
Overall, the new CMC-GLY lubricant eye gel was well tolerated and
eﬀective for relief of dry eye signs and symptoms. Acceptability results
indicated some transient blur with both CMC-GLY and CMC alone, but
otherwise there were no safety concerns and no treatment-related serious adverse events reported. CMC-GLY was noninferior and demonstrated faster improvement compared with the existing CMC-only formulation. These results support the use of CMC-GLY as an eﬀective
treatment to reduce signs and symptoms of dry eye disease.
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